Financing health tech has been saved
Financing health tech
Health care’s new frontier
Digital health technology companies saw a record year in funding in 2017. But other indicators were not as positive, including the number of health tech initial public offerings (IPOs): zero. This report takes a closer look at the current state of the health tech marketplace, as well as areas of disruption—and potential opportunity—for well-funded health tech companies.
- Financing digital health tech: A memorable year
- An environment ripe for disruption
- Some implications of health tech disruption
- Looking ahead: Three important questions
- Get in touch
Financing digital health tech: A memorable year
Digital health technology, or health tech, companies had a record-setting year in 2017 for funding health tech growth. A year-end report from venture fund Rock Health revealed some key insights into the sector, including:
- Funding of health tech companies was at an all-time high—$5.8 billion, up 32 percent over 2016.
- There were 8 megadeals—a record number to date—of more than $100 million.
- The average deal size was $16.7 million.
The growth of health tech funding, 2011–2017
Impressive numbers, to be sure. But not all news was as positive. The size and number of large, late-stage health tech deals appeared to be leveling off. Exits were down 18 percent in 2017, and all were due to mergers or acquisitions. Maybe most surprising, 2017 saw no health tech company IPOs. These last findings led Rock Health to indicate that:
For now, M&A is the new digital health IPO
Yet perhaps the lack of IPOs isn’t that surprising after all. Despite growth in the US stock markets, company executives and investors could be waiting until uncertainty in the US legislative and regulatory environment evens out, especially given efforts to repeal and replace the Affordable Care Act (ACA) and other initiatives of the new administration’s first year.
At the same time, consolidation in the broader health care industry continued among health care provider organizations, health plans, and life sciences companies, including pharmaceutical, biotech, and medical device companies. Convergence in those sectors continued as well, with traditional and non-traditional health care players expanding their industry footprint to gain economies of scale and control more of the continuum of services to health care consumers.
An environment ripe for disruption
That ongoing consolidation and convergence, along with three other “Cs” that are driving disruption in the industry (consumerism, cost, and compliance), still leave what is often called “white space” or opportunity in the industry as incumbent companies often focus more on reorganizing and less on technological innovation. It’s in that white space that well-funded digital health technology companies keep appearing, fueled by the expanding flow of private equity and venture capital funding.
Consider this: In almost all the US metro areas that are hotbeds of health tech company development, the number of funding deals at least doubled between the first and second half of 2017.
The five "Cs" of disruption
Funding health tech growth: Deals in most active US metro areas in 2017
Health tech companies, much like their cousins in other industries, including energy and resources, financial services (fintech), and insurance (insure tech), are shaking up long-standing business models and methods of health care, as well as where and how to access information.
Pent-up demand and
Top six funded value propositions in 2017
Why such an influx? From the perspective of private equity and venture capital investors,
Some implications of health tech disruption
The continued maturation and vibrancy of the health tech sector have important implications for incumbent companies. One is the broad change in ecosystems caused by health tech companies, which impacts both incumbents across sectors and even health techs themselves. Beyond a company’s supply chain, its ecosystem includes any person or entity that it interacts with: Staff, customers or patients, suppliers, affiliates or alliances, regulators… the list goes on.
In the future, the number of entities in the
The reality is that upstarts can be expected to appear wherever there’s friction in the ecosystem. Consider that five of the eight largest funding deals in 2017 involved health techs specializing in consumer health information, perhaps a natural result of individuals and families shouldering an increasing amount of responsibility for their health care. Incumbent firms should carefully consider who their customers are, where their competition could come from, and what’s keeping other organizations from taking their business away.
Financing digital health tech: Eight $100M+ mega deals of 2017
Looking ahead: Three important questions
With the future of health tech IPOs uncertain, three important questions arise about financing digital health tech in the future:
- Will the record-setting influx of investor dollars continue?
- Will acquisitions continue to be the exit strategy of choice?
- On a broader scale, what additional consolidation and convergence are likely to take place, and what role will the health tech sector play in that?
These questions should interest participants in the industry, including incumbents, non-traditional entrants, investors, and health techs themselves. The disruption caused by technology-driven entrants to the
Being prepared is key. Having an effective management team in place, along with appropriate systems, processes, talent, and governance will be critical. The ability to focus on and support the mission and goals of the organization is key, as is the increasing need to measure operational performance from a broader ecosystem perspective rather than the traditional business unit perspective.
For those health techs that find the right formula, the future is likely to be very bright indeed.
Prefer to read this report in PDF format? Download “Financing health tech: Health care’s new frontier.”
The services described herein are illustrative in nature and are intended to demonstrate our experience and capabilities in these areas, however due to independence restrictions that may apply to audit clients (including affiliates) of Deloitte & Touche LLP, we may be unable to provide certain services based on individual facts and circumstances.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms.